We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Drug Delivery System Targets Diseases at a Genetic Level

News   Dec 06, 2017 | Original story from University of Connecticut

 
New Drug Delivery System Targets Diseases at a Genetic Level

Enzyme-triggered degradation of a drug loaded peptide-crosslinked nucleic acid nanocapsule. First a peptide is crosslinked at the nanoparticle surface (1), then an enzyme recognizes the peptide crosslinker (2), and finally the enzyme cleavage leads to the release of the drug and any intact DNA (3). Credit: (Artwork by Joseph Luciani/UConn)

 
 
 

RELATED ARTICLES

Roots of Neuropsychiatric Risk in the Developing Brain

News

The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses such as autism spectrum disorders and schizophrenia.

READ MORE

Peeling Off Pesky Biofilms

News

Researchers have found a way to cleanly and completely peel off notoriously problematic biofilm sludges.

READ MORE

Precise Engineering of Graphene Could Benefit Lab-on-a-chip Applications

News

A team of NYU researchers has solved a longstanding puzzle of how to build ultra-sensitive, ultra-small electrochemical sensors with homogenous and predictable properties by discovering how to engineer graphene structure on an atomic level.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE